l e t t e r s
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancy in the developed world, accounting for 4% of the deaths from cancer in women 1 . We performed a three-phase genome-wide association study of EOC survival in 8,951 individuals with EOC (cases) with available survival time data and a parallel association analysis of EOC susceptibility. Two SNPs at 19p13.11, rs8170 and rs2363956, showed evidence of association with survival (overall P = 5 × 10 -4 and P = 6 × 10 -4 , respectively), but they did not replicate in phase 3. However, the same two SNPs demonstrated genome-wide significance for risk of serous EOC (P = 3 × 10 -9 and P = 4 × 10 -11 , respectively). Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development.
Factors related to tumor aggressiveness, response to therapy and underlying patient health are major predictors of survival in EOC. Germline genetic variation could affect every step in disease progression, from the likelihood of secondary mutational events to host tissue tolerance of a metastatic lesion and treatment response. Evidence for the role of germline genetics comes from the observations that rare EOC predisposition alleles of BRCA1 and BRCA2 are associated with improved overall survival following a diagnosis of EOC 2, 3 . Many studies have investigated the association between common genetic variation in candidate genes and EOC survival, but no positive findings have been convincingly replicated. Genome-wide association studies (GWAS) have successfully identified common genetic variants influencing a spectrum of phenotypes 4 , but to date there are no published reports of GWAS for cancer survival outcomes.
We conducted a three-phase GWAS to identify SNPs associated with variation in the time from invasive EOC diagnosis to death ( Supplementary Tables 1 and 2) . Genotyping was carried out in parallel with a multiphase GWAS of EOC susceptibility 5 . Phase 1 comprised 1,768 cases with invasive EOC from four UK studies. Survival time data, predominantly gathered through routine notification of deaths through the Office of National Statistics, was available for 86% of the cases. Controls were taken from two studies previously used as part of a GWAS for other phenotypes: the UK 1958 Birth Cohort and the UK Colorectal Control Cohort. Cases were genotyped using the Illumina Infinium 610K array and controls were genotyped using the similar Illumina 550K array [5] [6] [7] .
Associations between SNP genotypes and survival were evaluated using a 1 degree-of-freedom trend test based on the Cox model (Online Methods). The 4,649 SNPs showing the strongest evidence for association with EOC survival were selected for genotyping in phase 2 together with 22,790 SNPs selected for the susceptibility study and 800 SNPs that are highly informative on ancestry. Phase 2 comprised 4,238 cases and 4,810 controls from ten different studies across the United States, Europe and Australia, and SNPs were genotyped in phase 2 using a custom Illumina iSelect array. The majority of cases (80%) had survival time data available through a variety of sources, including death certificate flagging and medical records. Finally, we genotyped the three SNPs most strongly associated with survival, rs1125436, rs8170 and rs2363956, in a phase 3 analysis that included 4,501 cases (of which 4,076 had survival time data) and 6,021 controls from 22 additional studies that are part of the Ovarian Cancer Association Consortium. rs10426843 and rs8100241, which correlate perfectly with rs8170 and rs2363956, respectively, were included as proxies in the event of assay failure. We also genotyped 30 SNPs from the top nine loci from the analysis of susceptibility 8 . Genotyping of rs2363956 was poor in the phase 3 studies genotyped by iPlex (see Online Methods and Supplementary Note), so we used genotype data for the surrogate marker in our analyses.
Characteristics of the cases by study phase are shown in Supplementary Table 1 . Cases from all three phases provided 21,127 person-years of follow up; 3,358 deaths occurred within five years following diagnosis of EOC in the combined dataset. There was little evidence of any general inflation of the survival test statistics in either phase 1 or phase 2 (estimated inflation factor phase 1 λ 1,000 = 0.99, phase 2 λ 1,000 = 0.99) (Supplementary Fig. 1 ). In the analysis of the combined phase 1 and 2 data, the SNP most strongly associated with risk of death was rs1125436 at 13q32 (hazard ratio (HR) = 1.22, 95% CI 1.12-1.32, P = 3 × 10 -6 ). There was no association of this SNP with EOC susceptibility (P = 0.57). The next most strongly associated locus with survival was at 19p13 containing rs8170 (risk allele T) and rs2363956 (risk allele T) (HR = 1.18, 95% CI 1.09-1.27, P = 2 × 10 -5 and HR = 1.13, 95% CI 1.06-1.21, P = 2 × 10 -4 , respectively). Neither SNP reached the threshold of significance in phase 1 to be selected for phase 2 of the EOC susceptibility GWAS, but in the combined phase 1 and 2 data, both showed some evidence for susceptibility to EOC (odds ratio (OR) = 1.15, 95% CI 1.08-1.23, P = 7 × 10 -6 and OR = 1.08, 95% CI 1.03-1.14, P = 2 × 10 -3 , respectively). This association was stronger among ovarian cancers with serous histology (OR = 1.22, 95% CI 1.13-1.31, P = 1 × 10 -7 and OR = 1.14 95% CI 1.07-1.21, l e t t e r s P = 2 × 10 -5 , respectively). These effects were similar in analyses unadjusted for population stratification by principal components (data not shown). Risk allele frequencies of these SNPs in cases and controls by study are shown in Supplementary Table 3 .
In the phase 3 data, there was no evidence for the association of rs1125436, rs8170 or rs2363956 with survival time (P = 0.12, P = 0.85 and P = 0.25, respectively), and the effect of rs1125436 was in the opposite direction as found in phases 1 and 2 (data not shown). The direction of the survival effect was the same for rs8170 and rs2363956, and the effect size was larger in phase 1 as compared to phase 2 and 3 ( Supplementary Fig. 2b ). In the combined analysis of all three phases, rs8170 and rs2363956 showed similar levels of association with survival (HR = 1.11, 95% CI 1.04-1.17, P = 5 × 10 -4 and HR = 1.09, 95% CI 1.04-1.14, P = 6 × 10 -4 , respectively; Table 1 ). The association with survival was not attenuated after adjusting for tumor grade, tumor stage, age at diagnosis and histology.
The phase 3 data, however, provided strong support for the association of rs8170 and rs2363956 with EOC susceptibility ( Table 1) . This association was considerably stronger when the analysis was restricted to only serous cases, and the association for both SNPs reached genome-wide significance in the combined data analysis of serous cases only (P = 3 × 10 -9 and P = 4 × 10 -11 , respectively). These two SNPs remained highly significant (P < 10 -9 ) after a conservative Bonferroni correction for three tests (accounting for testing of all cases, serous cases and non-serous cases). There was little evidence of association with other histological subtypes ( Table 2) . No heterogeneity was seen in the OR for serous EOC risk or in the HR estimates for rs2363956 ( Supplementary Fig. 2a,b) or rs8170 among studies in any phase (forest plots not shown). rs8170 and rs2363956 are separated by 4 kb and are weakly correlated (r 2 = 0.23). In multivariate models, the associations with susceptibility to serous cancer and survival could not be fully explained by either SNP alone. rs8170 localizes to C19orf62, also known as MERIT40, a gene with five distinct transcripts described to date (Fig. 1a) . Depending on the alternative splice form, rs8170 is either synonymous (Lys279Lys) or non-synonymous (Ser281Arg). It may also act as an exonic splice enhancer (see URLs). rs2363956 is a non-synonymous SNP (Trp184Leu) in ANKLE1. Both tryptophan and leucine are neutral and nonpolar, suggesting this is a conservative change. Three recent reports have described interactions between MERIT40 and a complex including BRCA1, RAP80, BRCC45 and CCDC98 [9] [10] [11] . MERIT40 appears to regulate the retention of BRCA1 at double-strand DNA breaks (DSBs) and maintain the stability of this complex at the sites of DNA damage. Our data that suggest that common genetic variants in C19orf62 may predispose women mainly to serous ovarian cancer are also consistent with a similar subtype specificity associated with inactivating germline BRCA1 mutations 12 .
Common genetic variants can influence the expression of target genes through both cis and trans regulation 13 . Because rs8170 in C19orf62 and rs2363956 in ANKLE1 are located in the coding regions of these genes, we were able to evaluate cis-regulating expression by l e t t e r s looking at both genotype-associated expression and differential allelic expression in 48 normal primary ovarian epithelial (POE) cell lines. We found no evidence of cis-regulated expression using either approach, although the power of these analyses was limited by the small sample size (Supplementary Table 4 and Supplementary Fig. 3 ). We used array comparative genomic hybridization (aCGH) analysis to evaluate genomic alterations at the 19p13.11 locus in 105 highgrade serous ovarian cancers. Forty-six percent of tumors showed copy number gain (amplification) of the p arm of chromosome 19, with a peak of amplification in the region containing C19orf62 and ANKLE1 (Fig. 1b,c) . This suggests that target genes in this region are functionally activated during tumor development. We compared the expression of C19orf62 and ANKLE1 in 48 POE cell lines and 23 ovarian cancer cell lines. Consistent with aCGH data, C19orf62 was significantly overexpressed in ovarian cancer cell lines compared to POE cell lines (P = 5 × 10 -9 ; Fig. 1d ), but there were no differences in the expression of ANKLE1 (P = 0.54; Fig. 1e ). The analysis of 216 serous ovarian tumors in data from The Cancer Genome Atlas (TCGA) Pilot Project also suggests that the expression of C19orf62 (but not ANKLE1) is elevated in the majority of EOCs compared to normal tissues (Fig. 1f) .
The data suggesting a role for C19orf62 in EOC development need to be treated with caution. The risk-associated SNPs within C19orf62 and ANKLE1 may represent markers in linkage disequilibrium with the true functional variant(s) and target genes at this locus. Based on resequencing data from the 1000 Genomes Project (see URLs), there are 15 SNPs perfectly correlated with rs8170 and 9 SNPs perfectly correlated with rs2363956. Thus, genotyping of additional SNPs will be required to fine map this region in order to nominate optimal variants to investigate for functionality in EOC. Table 5 ). Gene expression data from TCGA suggests other candidate genes that could be the targets of amplification at this locus, some of which some are plausible cancer-associated genes. These include NR2F6 (also known as EAR-2) 14 , which may be involved in regulation of disease progression in breast cancer, and TMEM16H, one of a family of transmembrane proteins that may be overexpressed in several cancers 15 .
We can only speculate on the possible functional role of C19orf62 in the initiation and development of serous subtype EOCs, if it is indeed the target susceptibility gene at the 19p13 locus. Any hypotheses involving this issue would need to consider the apparent paradox suggested by our data that C19orf62 is overexpressed in EOCs, whereas BRCA1 is expected to show loss of function in its role in the DSB repair pathway. MERIT40 appears to act downstream of polyubiquitination of DNA (which occurs at all DSBs) and upstream of BRCA1 10 . MERIT40 is necessary for BRCA1 assembly at γH2AX foci, although BRCA1 is not usually a stable member of this complex [9] [10] [11] . Overexpression of C19orf62 may ectopically stabilize mutant BRCA1 protein into the assembled complex. Because C19orf62 knockdown makes cells more sensitive to ionizing radiation 10, 11 , C19orf62 overexpression could have the opposite effect, protecting cells with dysfunctional BRCA1 and DSB repair activity and enabling them to tolerate more DNA damage.
The association between the 19p13 locus and survival was only apparent in phases 1 and 2 and did not reach genome-wide significance overall. The clear evidence of association with serous EOC risk suggests that the survival association could still be of interest, but further study will be required to clarify the magnitude of the association. We would not have detected the association at 19p13 with risk of EOC if SNPs in the region had not been selected for phase 2 because of 2 l e t t e r s their association with survival time. The failure to detect an association with susceptibility at 19p13 may simply be by chance: the power in phase 1 to detect an odds ratio of 1.12 (combined data estimate) at the P value threshold required for a SNP to be taken into phase 2 was 50%. This failure may also have been the result of other factors such as disease heterogeneity; the association was stronger for serous EOC, and our initial analysis of phase 1 data (for selection of SNPs for phase 2) was based on cases of all histological types. Furthermore, the majority of the phase 1 cases were prevalent and, if the association of this locus with survival time is real (but small), this would bias the susceptibility association toward the null.
These data add to a growing list of genetic loci with common susceptibility alleles for EOC. Our data suggesting that the BRCA1-interacting gene C19orf62 may be the gene underlying the genetic associations to EOC add weight to the importance of the 19p13 locus for susceptibility in EOC. This is further emphasized by the finding of researchers the accompanying article 16 
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Study design. The ovarian cancer case-control studies that participated in phases 1, 2 and 3 are summarized in Supplementary Table 2 . Phase 1 comprised invasive epithelial ovarian cancer cases from the UK and genotype data of controls from the UK from GWAS of other phenotypes. Phase 2 comprised ten case-control studies from the Ovarian Cancer Association Consortium (OCAC). Phase 3 comprised 16 case-control studies and five case-only studies from the OCAC. All studies provided data on age at diagnosis, date of blood draw, self-reported ethnic group and histological subtype. Tumor histology was collected for all cases based on pathology reports or central pathological review and was categorized according to the World Health Organization classification system for ovarian cancer 17 .
Genotyping. Genotyping for phase 1 cases was conducted using the Illumina Infinium 610K array at Illumina Corporation. Existing data from two sets of controls, genotyped on the Infinium 550k array, were used in phase 1 analyses: the Welcome Trust Case-Control Consortium 1958 Birth Cohort and a national colorectal control study. All cases were from the UK and were confirmed as invasive epithelial ovarian cancer. Genotyping in the phase 2 studies was conducted using a custom Illumina iSelect array at Illumina Corporation.
For four phase 3 studies (Familial Ovarian Tumor Study (TOR), North Carolina Ovarian Cancer Study (NCO), Mayo Clinic Ovarian Cancer Study (MAY) and Tampa Bay Ovarian Cancer Study (MOF)), genotype data were available from an independent, ongoing GWAS study that also used the Illumina Infinium 610K platform. Genotyping and quality control procedures were performed at the Mayo Clinic genotyping shared resource. deCODE ovarian cancer cases were assayed by single SNP genotyping on the Centaurus (Nanogen) platform, and controls were from a GWAS that used the HumanHap300 and HumanCNV370-Duo BeadArrays. rs2363956 was genotyped using ABI Taqman for five of the phase 3 case-only studies (Gilda Radner Hereditary Cancer Program (LAX), Pelvic Mass Study (PVD), Scottish Randomized Trial in Ovarian Cancer (SCO), Yale/New Haven Hospital Study (YAL) and additional cases from Hormones and Ovarian Cancer Prediction Study (HOP)). The remaining phase 3 studies were genotyped using Sequenom iPlex. Quality control procedures for all study phases are described in the Supplementary Note and Supplementary Table 6.
Population stratification. We used the program LAMP 18 to assign intercontinental ancestry to phase 1 samples based on the HapMap release no.22 genotype frequency data for European, African and Asian populations. LAMP was also used to assign ancestry to the phase 2 samples using the HapMap data from European (CEU), African (ASW), East Asian (JPT-CHB-CHD), Mexican (MEX) and Indian (GIH) populations. Subjects with less than 90% European ancestry were excluded. For both the phase 1 and 2 samples, we used ancestry informative markers (AIMs) to calculate principal components for the subjects of European ancestry. The first principle component explained 0.42% of the variability and was included as a covariate in subsequent association analyses. Subsequent principal components were not included, as they explained less variability and there was little difference in their eigenvalues. In the phase 3 dataset, we excluded samples if their self-reported ethnicity was anything other than non-Hispanic white.
Imputation. We imputed missing genotype data for all the common variants in HapMap for phase 1 samples in order to increase genome coverage. We used an in-house method that combines the features of fastPHASE 19 and IMPUTE 20 to impute the ungenotyped or missing SNPs using the phase 2 HapMap data (CEU), which contains phased haplotypes for 60 individuals on 2.5 million SNPs. For each imputed genotype, the expected number of minor alleles carried was estimated (weights). Genotyped SNPs were assigned weights of 0, 1 or 2, according to the actual number of minor alleles carried. We estimated the accuracy of imputation by calculating the estimated r 2 between the imputed and actual SNP. SNPs with r 2 < 0.64 were excluded (n = 152,401), leaving a total of 2,563,972 SNPs for phase 1 analysis.
Tests of association.
In the analysis of the phase 1 and phase 2 data, the effect of each SNP on time to mortality from all causes after EOC diagnosis was assessed using Cox regression, stratified by study and modeling the per-allele effect as log additive. The Cox proportional hazards assumption was evaluated by inspection of standard log-log plots. Individual level data for the deCODE study were not available and so for the analysis of the phase 3 data and for the combined analyses, each study was analyzed separately and the results were pooled by estimating an average of the study specific log e hazard ratios, with each weighted by the inverse of its variance. Because the EOC cases showed a variable time from diagnosis to study entry, we allowed for left truncation, with time at risk starting on date of diagnosis and time under observation beginning at the time of study entry. This generates an unbiased estimate of the hazard ratio, provided the Cox proportional hazards assumption is correct 21 . The analysis of phase 1 data was right censored at 10 years after EOC diagnosis. In subsequent analyses, we right censored at 5 years after diagnosis in order to reduce the number of non-EOC related deaths. We used logistic regression to test for association between genotype and case-control status. For phase 1 and 2 data, we adjusted for study phase and study by including phase and study specific indicators in the model. For phase 3 data, we analyzed each study separately and then pooled the results using an inverse-variance weighted average of the study specific log e odds ratios. aCGH analysis. aCGH analysis was performed using a whole genome tiling path microarray (see URLs)-consisting of 32,450 bacterial artificial chromosome (BAC) clones 22 . Regions containing >80% neoplastic cells were microdissected from formalin-fixed paraffin-embedded tumor tissue sections and DNA was extracted by proteinase K digestion. Tumor DNA and matching peripheral blood DNA were amplified using the GenomePlex Whole Genome Amplification Kit (Sigma) and fluorescently labeled using the BioPrime Total kit (Invitrogen). Microarrays were cohybridized with the labeled DNA as described previously 23 , scanned using a Scanarray Express laser scanner (Perking Elmer), and spot signal intensities were extracted using BlueFuse (BlueGnome). Raw data were analyzed using R (see URLs) and the Bioconductor packages MANOR, LIMMA, DNAcopy and CGHcall as described elsewhere. BAC clone locations were derived from NCBI Human Genome build 36 (HG18).
Gene expression analysis in POE and ovarian cancer cell lines. Normal POE cell lines were established from brushings of normal ovaries of patients undergoing total hysterectomies at the University College London Hospital (UCLH), UK. All ovaries were histologically confirmed as free of disease. UCLH ethical committee approval was given for the collection and analysis of all patient samples. Short-term cultures of POE cells were established as previously described 24 . The non-neoplastic status and epithelial (non fibroblastic) nature of cells was confirmed by staining for the markers CA125, CK18, FVIII and FSP. RNA was extracted from POE and ovarian cancer cell lines (Supplementary Table 4 ) using RNeasy Mini Kits (QIAgen). Reverse transcribed RNA was analyzed for candidate gene expression by semiquantitative real-time PCR using the Applied Biosystems 7900HT genetic analyzer. Gene expression was normalized against two endogenous controls, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin. Real time expression data were analyzed using the comparative Δ-Δ Ct method. The expression values for genes in all cell lines are relative to either the lowest or highest expression of a POE cell line, normalized against GAPDH and β-actin. Differences in the relative expression of each candidate gene between EOC and POE cell lines were assessed using the nonparametric two-sided Wilcoxon rank-sum test using R. For allele-specific expression analysis, gene expression was calculated relative to the average expression of the common homozygotes for each candidate SNP, normalized against the expression of the endogenous control genes. Wilcoxon rank-sum tests were used to assess the difference in expression between common homozygotes, heterozygotes and rare homozygotes.
Differential allelic expression analysis in POE cell lines. For each SNP, 8 nanograms of cDNA from the heterozygous POE cell lines (10 lines for rs8170 and 15 lines for rs2363956) were analyzed by real time RT-PCR using TaqMan custom genotyping assays (Applied Biosystems). Genomic DNA extracted from lymphocytes from two heterozygous individuals was used for a standard curve to adjust for dye bias, as there would be equal copies of each allele. All samples were analyzed in triplicate. Differential allelic expression was
